Cardiol Therapeutics | WebDisclosure

PRESS RELEASE

published on 04/23/2025 at 15:24, 1 year 4 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates recommendation for Cardiol Therapeutics Inc, maintaining Buy rating and USD 8.50 target price. CardiolRxT phase III study enrollment for recurrent pericarditis (RP) shows promise for FDA approval

FDA Approval Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating CardiolRxT
BRIEF

published on 11/22/2024 at 11:11, 1 year 9 months ago

Cardiol Therapeutics obtient une note d'achat suite à des résultats d'essais prometteurs

Essais Cliniques Acheter Une Note CardiolRx Thérapeutique Cardiol Efficacité Des Médicaments
BRIEF

published on 11/22/2024 at 11:11, 1 year 9 months ago

Cardiol Therapeutics Secures Buy Rating Amid Promising Trial Results

Clinical Trials BUY Rating Cardiol Therapeutics CardiolRx Drug Efficacy
PRESS RELEASE

published on 11/22/2024 at 11:06, 1 year 9 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research reaffirms BUY rating for Cardiol Therapeutics Inc. with USD8.50 price target based on positive final data for CardiolRx in treating recurrent pericarditis

Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating Reaffirmed CardiolRx
BRIEF

published on 10/28/2024 at 15:51, 1 year 10 months ago

Cardiol Therapeutics lance un essai clinique de phase II/III pour la péricardite récurrente

Essai Clinique CardiolRx Péricardite Récurrente Thérapeutique Cardiol Essai MAVERIC-2
BRIEF

published on 10/28/2024 at 15:51, 1 year 10 months ago

Cardiol Therapeutics Initiates Phase II/III Clinical Trial for Recurrent Pericarditis

Clinical Trial Cardiol Therapeutics CardiolRx Recurrent Pericarditis MAVERIC-2 Trial
PRESS RELEASE

published on 10/28/2024 at 15:46, 1 year 10 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc., initiating phase II/III clinical trial for recurrent pericarditis treatment with CardiolRx

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Clinical Trial Pericarditis Treatment
BRIEF

published on 06/14/2024 at 14:57, 2 years 2 months ago

Cardiol Therapeutics Inc reçoit une note « d'achat » mise à jour de la part de First Berlin Equity Research

Acheter Une Note CardiolRx Cardiol Thérapeutique Péricardite Récurrente Étude De Phase II
BRIEF

published on 06/14/2024 at 14:57, 2 years 2 months ago

Cardiol Therapeutics Inc Receives Updated 'Buy' Rating from First Berlin Equity Research

BUY Rating Cardiol Therapeutics CardiolRx Recurrent Pericarditis Phase II Study
PRESS RELEASE

published on 06/14/2024 at 14:52, 2 years 2 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research increases Cardiol Therapeutics Inc's price target to USD8.50 in Buy recommendation after positive results from phase II trial of CardiolRx for recurrent pericarditis treatment

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Phase II Trial CardiolRx

Published on 09/05/2026 at 04:05, 2 days 12 hours ago

Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 2 days 17 hours ago

FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 2 days 17 hours ago

Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 2 days 18 hours ago

Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/04/2026 at 14:30, 3 days 2 hours ago

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

View all ACCESSWIRE

Published on 09/07/2026 at 16:10, 41 minutes ago

Redcare Pharmacy welcomes further progress on PoPP: New preliminary specification lays the groundwork for Health ID in remote care.
Published on 09/07/2026 at 16:02, 49 minutes ago

Original-Research: LAIQON AG (von First Berlin Equity Research GmbH): Buy
Published on 09/07/2026 at 16:01, 51 minutes ago

Holding(s) in Company
Published on 09/07/2026 at 16:00, 52 minutes ago

HUAWEI Mate XT 2 | ULTIMATE DESIGN Debuts as the First Smartphone to Feature LogicFolding Tau (τ) Chip and Reach Mass Commercialization
Published on 09/07/2026 at 15:26, 1 hour 26 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.

View all EQS

Published on 09/07/2026 at 15:03, 1 hour 48 minutes ago

voting rights
Published on 09/07/2026 at 15:03, 1 hour 48 minutes ago

droits de vote
Published on 09/07/2026 at 08:30, 8 hours 21 minutes ago

Dépôt d’une actualisation du document d’enregistrement universel
Published on 09/07/2026 at 08:25, 8 hours 26 minutes ago

Dépôt d’une actualisation du document d’enregistrement universel
Published on 09/07/2026 at 08:20, 8 hours 31 minutes ago

Derichebourg annonce le lancement d’une offre d’obligations vertes senior

View all LES ECHOS COMFI WIRE

News